RemeGen Co

RemeGen Co CapEx/OCF

The CapEx to Operating Cash Flow Ratio of RemeGen Co (688331.SS) as of Oct 26, 2026 is 355.87 %. In the previous year, CapEx to Operating Cash Flow Ratio was -22.49 % — a change of -1,682.63% (higher).

CapEx/OCF

355.87 %

YoY

-1,682.63%

Last updated:

CapEx to Operating Cash Flow Ratio of RemeGen Co is 2025 355.87 % . CapEx to Operating Cash Flow Ratio of RemeGen Co was 2024 -22.49 % . It decreases by -1,682.63% higher compared to the previous year.

The RemeGen Co CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-65.39 CNY
Jan 1, 2019
-23.06 CNY
Jan 1, 2020
-72.85 CNY
Jan 1, 2021
234.17 CNY
Jan 1, 2022
-59.94 CNY
Jan 1, 2023
-56.78 CNY
Jan 1, 2024
-22.49 CNY
Jan 1, 2025
355.87 CNY
The RemeGen Co CapEx/OCF history
YEARCapEx/OCFYoY
355.87 %-1,682.63%
-22.49 %-60.40%
-56.78 %-5.28%
-59.94 %-125.60%
234.17 %-421.46%
-72.85 %+215.86%
-23.06 %-64.73%
-65.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

CapEx to Operating Cash Flow Ratio of RemeGen Co is 355.87 % in 2025.

CapEx to Operating Cash Flow Ratio of RemeGen Co changed from -22.49 % to 355.87 %, representing a -1,682.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's RemeGen Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — RemeGen Co

All Key Metrics — RemeGen Co